Mird-226 !link!

While the MIRD-226 shows great promise, there are several challenges and limitations associated with its use, including:

represents the cross-disciplinary frontier where the Medical Internal Radiation Dose (MIRD) methodology meets the precision dosimetry, calculation data, and processing models for Radium-226 ( MIRD-226

: They help standardize practices across institutions, facilitating more uniform and comparable outcomes from radiopharmaceutical therapies and diagnostic procedures. While the MIRD-226 shows great promise, there are

Radionuclide therapy uses radioactive substances to treat disease, often targeting specific cells or tissues. One of the most well-established therapeutic radionuclides is Iodine-131 (¹³¹I), used primarily for the treatment of thyroid disorders, including thyroid cancer. While the MIRD-226 shows great promise

The foundational paradigm of MIRD segregates biological structures into two distinct categories: Source Regions (

The MIRD committee was formed under the auspices of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to standardize the methodology for calculating the absorbed dose from radiopharmaceuticals. The primary goal of the MIRD committee has been to provide guidelines and recommendations for the safe and effective use of radiopharmaceuticals in nuclear medicine. The committee's work has been instrumental in promoting the understanding and application of radiopharmaceutical dosimetry.